PT1658062E - Derivados de alfa-amino amida úteis como agentes antiinflamatórios - Google Patents

Derivados de alfa-amino amida úteis como agentes antiinflamatórios Download PDF

Info

Publication number
PT1658062E
PT1658062E PT04728870T PT04728870T PT1658062E PT 1658062 E PT1658062 E PT 1658062E PT 04728870 T PT04728870 T PT 04728870T PT 04728870 T PT04728870 T PT 04728870T PT 1658062 E PT1658062 E PT 1658062E
Authority
PT
Portugal
Prior art keywords
benzylamino
propanamide
fluorobenzyloxy
methyl
phenyl
Prior art date
Application number
PT04728870T
Other languages
English (en)
Portuguese (pt)
Inventor
Patricia Salvati
Orietta Veneroni
Elena Barbanti
Fariello Ruggero
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of PT1658062E publication Critical patent/PT1658062E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT04728870T 2003-08-25 2004-04-22 Derivados de alfa-amino amida úteis como agentes antiinflamatórios PT1658062E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49772203P 2003-08-25 2003-08-25

Publications (1)

Publication Number Publication Date
PT1658062E true PT1658062E (pt) 2010-03-31

Family

ID=34216147

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04728870T PT1658062E (pt) 2003-08-25 2004-04-22 Derivados de alfa-amino amida úteis como agentes antiinflamatórios

Country Status (21)

Country Link
US (2) US20070276046A1 (https=)
EP (1) EP1658062B1 (https=)
JP (1) JP5042625B2 (https=)
KR (1) KR101233711B1 (https=)
CN (1) CN1842328A (https=)
AT (1) ATE457724T1 (https=)
AU (1) AU2004266494B2 (https=)
BR (1) BRPI0413982A (https=)
CA (1) CA2536764C (https=)
CY (1) CY1109992T1 (https=)
DE (1) DE602004025586D1 (https=)
DK (1) DK1658062T3 (https=)
ES (1) ES2339021T3 (https=)
IL (1) IL173886A (https=)
NO (1) NO335245B1 (https=)
NZ (1) NZ545502A (https=)
PL (1) PL1658062T3 (https=)
PT (1) PT1658062E (https=)
RU (1) RU2396251C2 (https=)
SI (1) SI1658062T1 (https=)
WO (1) WO2005018627A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1658062T3 (da) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
CA2689561C (en) 2007-06-15 2015-11-17 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US8530701B2 (en) 2007-12-11 2013-09-10 Newron Pharmaceuticals, S.P.A. High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
SI2563355T1 (sl) 2010-04-27 2016-10-28 Newron Pharmaceuticals S.P.A. Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
DE102012108965B4 (de) 2012-09-24 2014-08-14 Exscitron Gmbh Stromquelle mit verbesserter Dimmvorrichtung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
SE9801494D0 (sv) * 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
RU2164512C1 (ru) * 1999-07-27 2001-03-27 Всероссийский научный центр по безопасности биологически активных веществ Производные аминокислот, проявляющие антиаритмическую активность
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
AU7804501A (en) * 2000-07-27 2002-02-13 Pharmacia Corp Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
SI1458386T1 (sl) * 2001-12-27 2007-08-31 Ortho Mcneil Pharm Inc Aroil pirol heteroeril in metanoli, uporabni za zdravljenje motnje centralnega živčnega sistema
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
DK1658062T3 (da) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
CA2689561C (en) * 2007-06-15 2015-11-17 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US8530701B2 (en) * 2007-12-11 2013-09-10 Newron Pharmaceuticals, S.P.A. High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
NZ586182A (en) * 2007-12-19 2012-02-24 Newron Pharm Spa Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

Also Published As

Publication number Publication date
US20100016440A1 (en) 2010-01-21
CY1109992T1 (el) 2014-09-10
KR20060128825A (ko) 2006-12-14
AU2004266494B2 (en) 2010-04-08
DK1658062T3 (da) 2010-05-31
NZ545502A (en) 2010-04-30
ES2339021T3 (es) 2010-05-14
DE602004025586D1 (de) 2010-04-01
KR101233711B1 (ko) 2013-02-18
PL1658062T3 (pl) 2010-07-30
NO20060896L (no) 2006-03-09
WO2005018627A8 (en) 2005-09-01
IL173886A (en) 2012-09-24
CA2536764C (en) 2013-09-17
RU2006105634A (ru) 2006-08-10
AU2004266494A1 (en) 2005-03-03
JP5042625B2 (ja) 2012-10-03
RU2396251C2 (ru) 2010-08-10
IL173886A0 (en) 2006-07-05
WO2005018627A1 (en) 2005-03-03
JP2007503424A (ja) 2007-02-22
CN1842328A (zh) 2006-10-04
CA2536764A1 (en) 2005-03-03
SI1658062T1 (sl) 2010-05-31
US20070276046A1 (en) 2007-11-29
ATE457724T1 (de) 2010-03-15
EP1658062A1 (en) 2006-05-24
NO335245B1 (no) 2014-10-27
BRPI0413982A (pt) 2006-11-07
EP1658062B1 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
US20100016440A1 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
ES2433080T3 (es) Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor
JP2013516488A (ja) 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療
JP2021526507A (ja) 発作により誘発される突然死を処置するための組成物および方法
ES2313330T3 (es) Derivados de alfa-aminoamida utiles en el tratamiento del sindrome de piernas inquietas.
JP2018507874A (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
CN100584323C (zh) 用于治疗下泌尿道病症的α-氨基酰胺衍生物
ES2347581T3 (es) Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
BRPI0317795B1 (pt) Derivados de alfa-aminoamida úteis como agentes antienxaqueca
HUT77317A (hu) Indolszármazékok alkalmazása különböző betegségek kezelésére alkalmas gyógyszer előállítására
EP3400940B1 (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
KR20170131240A (ko) 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
AU2017374458B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
BRPI0718199A2 (pt) Composição, e, métodos para estabilizar o ritmo da respiração de um mamífero, e para aumentar a ventilação por minuto no nível dos centros de controle respiratório do tronco cerebral no nucleus tractus solitarius de um indivíduo.
EP1247533A2 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
CN120225185A (zh) 5-甲氧基-2-氨基茚满(“meai”)在用于治疗代谢综合征的方法中的用途
ES2331369T3 (es) Medicina para prevencion o tratamiento de miccion frecuente o incontinencia urinaria.
CN113242735A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
MXPA06002189A (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
ES2362926T3 (es) Nueva combinación de fármacos como un antidepresivo.
MX2011002727A (es) Composicion farmaceutica novedosa para tratamiento de dolor nociceptivo.
Halesh A study of the effects of oral gabapentin and oral clonidine on preoperative anxiolysis and attenuation of stress response to endotracheal intubation
HK40000275B (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
BRPI0713695A2 (pt) preparação combinada, uso da mesma, e, composição farmacêutica
HK1103282B (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders